Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD19 CAR-T Cells for Relapsed/Refractory B-ALL
NCT03937544Phase 3Recruiting
- Sponsor
- Universiti Kebangsaan Malaysia
- Start
- Mar 2019
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 3 trial of CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Universiti Kebangsaan Malaysia. Started Mar 2019; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03937544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937544.